Proactive Investors - Run By Investors For Investors

Summit Therapeutics soars as it hails potential of very early stage antibiotic

The treatment has been developed to tackle a gram-negative bacteria that is becoming resistant to current drugs
research inspecting petri dish
The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases, taking place in Amsterdam

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) shares soared higher on Monday as the firm trumpeted the early success of a pre-clinical antibiotic that may help overcome drug resistance to a potentially deadly infection.

The group said it presented data at a leading healthcare conference that showed its treatment, DDS-04, had successfully tackled bacteria called Enterobacteriaceae in animals with urinary tract infections.

Resistant strain

Antimicrobial resistance means people contracting the gram-negative bacterial strain, which also affects the lungs and bloodstream, “are increasingly at risk for poor outcomes”, said Dr David Roblin, Summit’s head of research and development.

“Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy,” he explained. “There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes.”

The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases, taking place in Amsterdam.

In early afternoon trading in London, Summit shares were 17.3% higher at 32.25p.

 -- Adds share price --

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use